Lebensweise und Alzheimer

Zusammenfassung

Alzheimer ist eine Mangelkrankheit, verursacht durch Diskrepanzen zwischen unseren natürlichen Bedürfnissen und Folgen der heutigen Lebensweise: Chronischer Stress, ungesunde Ernährung, Mangel an Mikronährstoffen, Tiefschlaf, Bewegung, sozialen Aktivitäten sowie Verlust des Lebenssinns. Basierend auf einer Allgemeinen Theorie der Alzheimer-Entstehung (Unified Theory of Alzheimer‘s Disease, UTAD) beginnt die Erkrankung mit der gestörten Neubildung von Nervenzellen (Neurogenese) im hippocampalen Zentrum für das autobiografische Erinnern. Die mangelhafte adulte Neurogenese führt zunächst zu einem chronisch erhöhten Level an Stresshormonen, kurz- bis mittelfristig zu Depression und letztendlich zu den für Alzheimer typischen neuropathologischen und kognitiven Veränderungen. Durch gezieltes Beheben der individuellen Mängel (der kausalen Risikofaktoren) im Rahmen einer systembiologischen Intervention, lässt sich Alzheimer jedoch nicht nur vermeiden, im Frühstadium der Erkrankung ist der geistige Abbau sogar noch umkehrbar.

Abstract

Alzheimer’s disease (AD) is a deficiency disease, caused by a discrepancy between our natural requirements and individual consequences of our modern way of life, like e. g. chronic stress, unhealthy nutrition, deficiencies in micronutrients, deep sleep as well as physical and social activities, but also a loss of purpose in life. According to the Unified Theory of AD (UTAD), AD is caused by a disturbed generation of neurons (neurogenesis) in the center of autobiographic memory (Hippocampus). Impaired adult hippocampal neurogenesis causes chronically elevated stress hormone levels, which lead to psychological depression in the short- to mid-term and end in AD-typical neuropathological and cognitive alterations. By targeted correction of all individual deficiencies (causal risk factors) by a systems biological intervention strategy, AD can be prevented and the cognitive decline reversed at least in the early phase of the disease.

Schlüsselwörter

Alzheimer-Demenz - adulte Neurogenese - Hippocampus - Alzheimer-Prävention - Alzheimer-Therapie

Keywords

Alzheimer’s disease (AD) - adult neurogenesis - Hippocampus - prevention of AD - AD-therapy

• Literatur

• 1 James BD, Leurgans SE, Hebert LE. et al. Contribution of Alzheimer disease to mortality in the United States. Neurology 2014; 82: 1045-1050
• 2 Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurol Centralbl 1906; 25: 1134
• 3 Boyd W. A Textbook of Pathology: An Introduction to Medicine, Lea and Febiger. 1938
• 4 Grant WB. Trends in diet and Alzheimer’s disease during the nutrition transition in Japan and developing countries. J Alzheimers Dis 2014; 38: 611-620
• 5 Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 1996; 165: 3-12
• 6 O‘Brien JT, Firbank MJ, Davison C. et al. 18 F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med 2014; 55: 1959-1965
• 7 Bartzsch O, Gertheiss J, Calabrese P. Wert und Akzeptanz einer Alzheimer-Risikodiagnostik. Der Nervenarzt 2015; 86: 1549-1554
• 8 Nehls MN. Unified theory of Alzheimer‘s disease (UTAD): implications for prevention and curative therapy. J Mol Psychiatry 2016; 4: 3
• 9 Bredesen DE, Amos EC, Canick J. et al. Reversal of cognitive decline in Alzheimer‘s disease. Aging 2016; 8: 1250-1258
• 10 Puzzo D, Arancio O. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?. J Alzheimers Dis 2013; 33: 111-120
• 11 Tu S, Okamoto S, Lipton SA. et al. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer‘s disease. Mol Neurodegener 2014; 9: 48
• 12 Sevigny J, Chiao P, Bussière T. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer‘s disease. Nature 2016; 537: 50-56
• 13 Alzheimer-Therapie: Hoffnungsträger scheitert in Phase III. Im Internet: http://www.pharmazeutische-zeitung.de/index.php?id=66334 Stand: 24.11.2016
• 14 Lahdenperä M, Lummaa V, Helle S. Fitness benefits of prolonged post reproductive lifespan in women. Nature 2004; 428: 178-181
• 15 Gurven M, Kaplan H. Longevity among hunter-gatherers: A cross-cultural examination. Population and Development Review 2007; 33: 321-365
• 16 Spalding KL, Bergmann O, Alkass K. et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 2013; 153: 1219-1227
• 17 Du X, Pang TY. Is dysregulation of the HPA-axis a core pathophysiology mediating co-morbid depression in neurodegenerative diseases?. Front Psychiatry 2015; 6: 32
• 18 Dranovsky A, Leonardo ED. Is there a role for young hippocampal neurons in adaptation to stress?. Behav Brain Res 2012; 227: 371-375
• 19 Hill AS, Sahay A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to reduce anxiety and depression-like behaviors. Neuropsychopharmacol 2015; 40: 2368-2378
• 20 Zahodne LB, Stern Y, Manly JJ. Depressive symptoms precede memory decline, but not vice versa, in non-demented older adults. J Am Geriatr Soc 2014; 62: 130-134
• 21 Walker LC, Diamond MI, Duff KE. et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013; 70: 304-310
• 22 Stöhr J, Watts JC, Mensinger ZL. et al. Purified and synthetic Alzheimer‘s amyloid beta (Aβ) prions. Proc Natl Acad Sci USA 2012; 109: 11025-11030
• 23 Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 693-701 Conner TS, Richardson AC, Miller JC. Optimal serum selenium concentrations are associated with lower depressive symptoms and negative mood among young adults. J Nutr 2015; 145:59–65
• 24 Zhu Y, Zhou R, Yang R. et al. Abnormal neurogenesis in the dentate gyrus of adult mice lacking 1,25-dihydroxy vitamin D3 (1,25-(OH)2 D3). Hippocampus 2012; 22: 421-433 Littlejohns TJ, Henley WE, Lang IA. et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014; 83:920–928
• 25 Smith AD, Smith SM, de Jager CA. et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010; 0 DOI: 10.1371/journal.pone.0012244; Shin JY, Ahn YH, Paik MJ. et al. Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model, PLoS One 2012; DOI: 10.1371/journal.pone.0050496
• 26 Fiorentini A, Rosi MC, Grossi C. et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One 2010; DOI: 10.1371/journal.pone.0014382 0
• 27 Ishii N, Terao T, Araki Y. et al. Low risk of male suicide and lithium in drinking water. JClin Psychiatry 2015; 76: 319-326
• 28 Terao T. Is lithium potentially a trace element?. World J Psychiatry 2015; 5: 1-3 Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res 2013; 10:104–107
• 29 Nehls M. Die Alzheimer-Lüge. Die Wahrheit über eine vermeidbare Krankheit. Heyne; 2014
• 30 Nehls M. Alzheimer ist heilbar. Rechtzeitig zurück in ein gesundes Leben. Heyne; 2015
• 31 Therapien gegen das große Vergessen. Was hilft bei Alzheimer?. Im Internet: www.swr.de/swr2/programm/sendungen/wissen/alzheimer-stand/-/id=660374/did=17944114/nid=660374/4hadoa/index.html Stand: 24.11.2016
• 32 Alzheimer-Therapie nach Nehls (ATnN) - Ärzte und Therapeuten. Im Internet: www.michael-nehls.de/atnn-netzwerk.htm Stand: 24.11.2016